7 Healthcare AI Stocks Under $50 With Huge Upside Potential

Quick Read

• Dislocation between share price and product progress is exactly the kind of setup retail investors should scan for.

• Here are seven healthcare AI stocks trading under $50 where the bull case is grounded, not hype.

• The analyst who called NVIDIA in 2010 just named his top 10 stocks and AbCellera Biologics wasn't one of them. Get them here FREE.

Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product progress is exactly the kind of setup retail investors should scan for: real revenue, real partnerships, and prices low enough that a successful multi-year execution path can plausibly deliver triple-digit returns. The $50 ceiling is the filter; the AI flywheel is the thesis.

With that in mind, here are seven healthcare AI stocks trading under $50 where the bull case is grounded in product, partnership, or platform data, not hype.

Tempus AI

Tempus AI (NASDAQ: TEM) pairs genomic diagnostics with a massive healthcare data library that pharma partners license for AI-driven drug discovery. At around $43.93, shares are down 25.6% year to date and are well below the $67.20 analyst target price, with 10 Buy or Strong Buy ratings against one Sell.

The analyst who called NVIDIA in 2010 just named his top 10 stocks and AbCellera Biologics wasn't one of them. Get them here FREE.

Q4 2025 revenue grew 83% year over year to $367.21 million, adjusted EBITDA flipped positive at $12.89 million, and 2026 guidance calls for $1.59 billion in revenue and roughly $65 million in adjusted EBITDA. CEO Eric Lefkofsky said "network effects from our investments in AI continue to compound," backed by deepening partnerships with Gilead, Merck, and Daiichi Sankyo. The risk is that an accumulated deficit of $2.4 billion, heavy stock-based comp, and the $460 million in convertible notes priced in May 2026 add dilution and execution risk. Still, the data flywheel keeps spinning.

Hims & Hers Health

Hims & Hers Health (NYSE: HIMS) runs a direct-to-consumer telehealth platform that uses AI to personalize care across weight loss, dermatology, mental health, and sexual wellness. At about $25.05 a share, the stock is down 57.2% over one year, with a forward P/E near 48x.

FY2026 guidance was raised to $2.80 billion to $3.00 billion in revenue and $275 million to $350 million in adjusted EBITDA, and management is targeting $6.5 billion in revenue and $1.3 billion adjusted EBITDA by 2030. International revenue surged 969% to $78.19 million, and a $250 million buyback was authorized. CEO Andrew Dudum called 2026 "a defining year." The bull case is based on subscriber growth, the Novo Nordisk branded GLP-1 partnership, and international scaling. Notably, Q1 2026 EPS missed consensus estimates by 396.74%, U.S. revenue declined, and ongoing FDA and securities lawsuits around compounded GLP-1s remain unresolved.